These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20872175)

  • 21. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-Induced Cyr61/CCN1 Production in Infantile Hemangioma.
    Wu P; Xu H; Li N; Huo R; Shen B; Lin X; Ma G
    Plast Reconstr Surg; 2021 Mar; 147(3):412e-423e. PubMed ID: 33587560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines.
    Kojima K; Fujino Y; Goto-Koshino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2013; 75(6):727-31. PubMed ID: 23337362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines.
    Lun M; Zhang PL; Siegelmann-Danieli N; Blasick TM; Brown RE
    Ann Clin Lab Sci; 2005; 35(1):15-24. PubMed ID: 15830705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
    Zhu L; Xie J; Liu Z; Huang Z; Huang M; Yin H; Qi W; Yang Z; Zhou T; Gao G; Zhang J; Yang X
    Cancer Sci; 2018 Jun; 109(6):1981-1994. PubMed ID: 29664206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
    Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.
    Zhang W; Chen G; Wang FQ; Ren JG; Zhu JY; Cai Y; Zhao JH; Jia J; Zhao YF
    J Invest Dermatol; 2015 Dec; 135(12):3163-3172. PubMed ID: 26288359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propranolol Accelerats Hemangioma Stem Cell Transformation Into Adipocyte.
    Li HH; Lou Y; Zhang RR; Xie J; Cao DS
    Ann Plast Surg; 2019 Nov; 83(5):e5-e13. PubMed ID: 31609806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Lun M; Zhang PL; Pellitteri PK; Law A; Kennedy TL; Brown RE
    Ann Clin Lab Sci; 2005; 35(3):251-8. PubMed ID: 16081580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
    Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
    Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma.
    Zhang L; Wu HW; Yuan W; Zheng JW
    Cancer Manag Res; 2017; 9():279-286. PubMed ID: 28744158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D analogue TX 527 down-regulates the NF-κB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus.
    González-Pardo V; Verstuyf A; Boland R; Russo de Boland A
    Br J Pharmacol; 2013 Aug; 169(7):1635-45. PubMed ID: 23647513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
    Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemangioma Endothelial Cells and Hemangioma Stem Cells in Infantile Hemangioma.
    Sun Y; Qiu F; Hu C; Guo Y; Lei S
    Ann Plast Surg; 2022 Feb; 88(2):244-249. PubMed ID: 35023872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.
    Sung MH; Bagain L; Chen Z; Karpova T; Yang X; Silvin C; Voss TC; McNally JG; Van Waes C; Hager GL
    Mol Pharmacol; 2008 Nov; 74(5):1215-22. PubMed ID: 18684839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.